Guarantee drug companies a profit to develop new antibiotics UK report says

first_img Email Ever-evolving bacteria have left doctors desperate for new drugs, and a new report commissioned by the government of the United Kingdom lays out a plan for how to get them: Global governments should unite to offer multibillion-dollar incentives for drug developers, and pharmaceutical companies should pool their billions in support of early-stage research. The analysis—the third in a series from a commission established by U.K. Prime Minister David Cameron and chaired by former Goldman Sachs economist Jim O’Neill—is the most specific and prescriptive yet, laying out what it calls “a bold set of interventions” to get new drugs to market.The problem of antimicrobial resistance has received a global spotlight lately as cases of highly resistant infections mount. The White House rolled out a new antibiotic resistance budget initiative in January, following the creation of an interagency task force last year.Unfortunately, the development of new drugs has stalled, partially for economic reasons: New therapies are costly and risky to develop, but when they reach the market, they compete with cheap generic drugs that doctors prefer to use for all but the more dire resistant infections. The new report starts with the premise that the world needs 15 new antibiotics per decade, at least four of which should have new mechanisms of action to target the most harmful pathogens, such as Klebsiella pneumoniae and Escherichia coli. Click to view the privacy policy. Required fields are indicated by an asterisk (*) Country * Afghanistan Aland Islands Albania Algeria Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia, Plurinational State of Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, the Democratic Republic of the Cook Islands Costa Rica Cote d’Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See (Vatican City State) Honduras Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic People’s Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People’s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, the former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Martinique Mauritania Mauritius Mayotte Mexico Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Norway Oman Pakistan Palestine Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Qatar Reunion Romania Russian Federation Rwanda Saint Barthélemy Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Martin (French part) Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten (Dutch part) Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania, United Republic of Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Vietnam Virgin Islands, British Wallis and Futuna Western Sahara Yemen Zambia Zimbabwecenter_img Sign up for our daily newsletter Get more great content like this delivered right to you! Country As a “pump-priming” measure, the report suggests a $2 billion “global innovation fund,” bankrolled by pharmaceutical companies, to conduct fundamental research on bacterial resistance, improve diagnostics to identify resistant strains, and revisit old antibiotics the development of which has stalled.To incentivize drug development without encouraging overuse, the report promotes an idea gaining popularity in antibiotics: “de-linking” a drugmaker’s profits from the drug’s sales. Such strategies aim to give companies assurance that they will make money if they bring valuable new antibiotics to market, regardless of the number of pills prescribed right away. The report suggests two strategies: A “designated global body” could buy the rights to a drug from a pharmaceutical company—for a suggested $2 billion to $3 billion per antibiotic—and carefully control its supply. Or, a company would retain the rights to sell its drug, but receive an additional lump sum reward—a suggested $1 billion to $1.3 billion—for introducing it.“This is a happy moment,” wrote Boston University health law professor Kevin Outterson in a blog post in response to the report. Outterson, who has long promoted de-linkage, says its publication “marks a watershed event as an authoritative endorsement of the principle.”Meanwhile, a public-private partnership between the European Union and the European pharmaceutical industry is already exploring how to implement de-linkage strategies through a project called “driving reinvestment in research and development and responsible antibiotic use” (DRIVE-AB), which held its first meeting in October.last_img